IceCure Medical Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ICCM in the last 30 days.
See all $ICCM insider activity →IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.
IceCure Medical (ICCM) signed an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. The deal aims to expand ProSense® commercialization in a market with growing interest in minimally invasive cancer treatments. The THERMAC trial, in Phase III, supports cryoablation's potential for early-stage breast cancer treatment, with a 94% success rate.
IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ICCM (IceCure Medical Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ICCM coverage spans earnings, technology and regulation.
Approval is likely to boost sales and improve cash flow, supporting a price upside.
The deal expands IceCure's European footprint and could boost sales of its ProSense® system, especially as the THERMAC trial moves into Phase III.
Positive regulatory step may boost future sales and investor sentiment for IceCure.
Revenue growth and new financing improve short-term liquidity but net loss and cash runway raise going‑concern concerns.
The PR is supportive for ProSense adoption, but it is primarily promotional around already-disclosed regulatory and trial context rather than a new approval or datapoint.
AlphAI scores every news story that mentions ICCM with an AI model for sentiment and relevance, and aggregates insider trades from IceCure Medical Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.
1 min readIceCure Medical (ICCM) signed an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. The deal aims to expand ProSense® commercialization in a market with growing interest in minimally invasive cancer treatments. The THERMAC trial, in Phase III, supports cryoablation's potential for early-stage breast cancer treatment, with a 94% success rate.
2 min readIceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.
2 min readIceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.
3 min readIceCure Medical (NASDAQ: ICCM) said two peer-reviewed publications support cryoablation for breast cancer de-escalation. The first cites FDA marketing authorization for ProSense and inclusion in updated ASBrS guidelines, referencing ICE3 five-year results with a 3.1% IBTR rate. The second discusses cryoablation for axillary lymph node metastases.
2 min readIceCure Medical (ICCM) reported six-month results ended June 30, 2026. Revenue rose 45% year over year to $1.8 million from $1.24 million. Gross profit increased to $548,000 from $349,000, helped by higher ProSense system and disposable probe sales. Cash was $12.0 million. The company said U.S. footprint grew 70% and it is advancing its CHoICE post-marketing study.
4 min readIceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.
7 min readIceCure Medical Ltd. (ICCM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U
3 min readIceCure Medical Ltd. (Nasdaq: ICCM) said Adventist Health Glendale in California signed an agreement and received IRB approval to become the first U.S. site enrolling patients in its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer. The study will enroll up to 400 patients across multiple sites to generate real-world data after FDA marketing authorization in Oct. 2025.
3 min readIceCure Medical (Nasdaq: ICCM) said the Society of Interventional Oncology submitted a petition to the NCCN Breast Cancer Guidelines Panel to add percutaneous cryoablation without surgical excision as a Category 2B option. The proposal targets patients 70+ meeting specific low-risk tumor criteria, and 50-69 poor surgical candidates or surgery decliners with cryoablation plus whole-breast radiation and endocrine therapy, citing FDA clearance of its ProSense system in Oct 2025.
3 min read
